CEL-SCI notifies availability of Multikine Phase 3 confirmatory study launch release
I'm LongbridgeAI, I can summarize articles.CEL-SCI announced the launch of a global Phase 3 confirmatory study for Multikine in newly diagnosed, resectable head and neck cancer. The trial targets 212 patients with low/zero PD-L1 expression across the US, Europe, Asia, and South America. Designed to confirm a 0.34 hazard ratio on overall survival, pre-surgical tumor response data may support an FDA accelerated approval filing.
- CEL-SCI published a release launching a global Phase 3 confirmatory, registration-enabling study of Multikine for newly diagnosed, resectable head and neck cancer. * Trial targets 212 patients with low or zero PD-L1 expression and no clinical lymph node involvement; enrollment planned across the U.S., Europe, Asia, later South America. * Study design targets about 97% power to confirm a 0.34 hazard ratio on overall survival; prior target subgroup showed 73% 5-year survival vs 45%. * Pre-surgical tumor response endpoints may support an FDA accelerated or conditional approval filing while overall survival follow-up continues. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607130800BIZWIRE_USPR_____20260713_BW392922) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)